RU2005140518A - Композиции и способы, включающие соединения гастрина - Google Patents

Композиции и способы, включающие соединения гастрина Download PDF

Info

Publication number
RU2005140518A
RU2005140518A RU2005140518/15A RU2005140518A RU2005140518A RU 2005140518 A RU2005140518 A RU 2005140518A RU 2005140518/15 A RU2005140518/15 A RU 2005140518/15A RU 2005140518 A RU2005140518 A RU 2005140518A RU 2005140518 A RU2005140518 A RU 2005140518A
Authority
RU
Russia
Prior art keywords
gastrin
weeks
subject
compound
composition according
Prior art date
Application number
RU2005140518/15A
Other languages
English (en)
Russian (ru)
Inventor
Антонио КРУЗ (CA)
Антонио КРУЗ
Original Assignee
Уэйрейта Фармасьютиклз, Инк. (Ca)
Уэйрейта Фармасьютиклз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/016660 external-priority patent/WO2003100024A2/en
Application filed by Уэйрейта Фармасьютиклз, Инк. (Ca), Уэйрейта Фармасьютиклз, Инк. filed Critical Уэйрейта Фармасьютиклз, Инк. (Ca)
Publication of RU2005140518A publication Critical patent/RU2005140518A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2005140518/15A 2003-05-27 2004-05-27 Композиции и способы, включающие соединения гастрина RU2005140518A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
USPCT/US03/16660 2003-05-27
PCT/US2003/016660 WO2003100024A2 (en) 2002-05-24 2003-05-27 Treatment for diabetes

Publications (1)

Publication Number Publication Date
RU2005140518A true RU2005140518A (ru) 2007-07-10

Family

ID=33488788

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005140518/15A RU2005140518A (ru) 2003-05-27 2004-05-27 Композиции и способы, включающие соединения гастрина

Country Status (11)

Country Link
EP (1) EP1648495A2 (https=)
JP (1) JP2007513059A (https=)
CN (1) CN1829528A (https=)
AU (1) AU2004243541A1 (https=)
BR (1) BRPI0410710A (https=)
CA (1) CA2527186A1 (https=)
MX (1) MXPA05012605A (https=)
NO (1) NO20055582L (https=)
PL (1) PL379145A1 (https=)
RU (1) RU2005140518A (https=)
WO (1) WO2004105780A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156828A0 (en) 2001-01-12 2004-02-08 Waratah Pharmaceuticals Inc Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes
EP1837031B1 (en) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
US7560425B2 (en) 2002-06-07 2009-07-14 Waratah Pharmaceuticals Inc. Pharmaceutical composition consisting of rapamycine and gastrin 17(LEU15) and a method for treating diabetes
US20090202494A1 (en) * 2004-01-30 2009-08-13 Antonio Cruz Combined use of glp-1 agonists and gastrin for regulating blood glucose levels
WO2008106779A1 (en) * 2007-03-02 2008-09-12 Waratah Pharmaceuticals Inc. Gastrin compound for diabetes treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
DE69431212T2 (de) * 1994-01-24 2003-04-10 The General Hospital Corp., Boston Behandlung von diabetes
IL156828A0 (en) * 2001-01-12 2004-02-08 Waratah Pharmaceuticals Inc Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes
KR20050074492A (ko) * 2002-10-22 2005-07-18 와라타 파마수티컬즈, 인크. 당뇨병의 치료

Also Published As

Publication number Publication date
EP1648495A2 (en) 2006-04-26
BRPI0410710A (pt) 2006-06-13
WO2004105780A2 (en) 2004-12-09
AU2004243541A1 (en) 2004-12-09
CN1829528A (zh) 2006-09-06
CA2527186A1 (en) 2004-12-09
JP2007513059A (ja) 2007-05-24
PL379145A1 (pl) 2006-07-24
MXPA05012605A (es) 2006-02-22
NO20055582D0 (no) 2005-11-25
NO20055582L (no) 2006-02-27
WO2004105780A3 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
ES2320754T3 (es) Tratamiento de la diabetes.
US9522175B2 (en) Method of enhancing diabetes resolution
US8202837B2 (en) Methods for administering hypoglycemic agents
CN102421797A (zh) Glp-1类似物的衍生物或其可药用盐和用途
SG187904A1 (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
JP2007519642A5 (https=)
CN106279400A (zh) P8降糖肽的设计及其用途
RU2005140518A (ru) Композиции и способы, включающие соединения гастрина
Prajapati et al. Current status of therapeutic peptides for the management of diabetes mellitus
AU2020344895B2 (en) Treatment of type 2 diabetes mellitus
KR102327750B1 (ko) Glp-1 유사체를 포함하는 경구투여용 약제학적 조성물
WO2024254352A1 (en) Sglt1 inhibitor and incretin combinations for treating metabolic disease
JP2007513059A5 (https=)
Chakraborti Exenatide: a new promising antidiabetic agent
Pitocco et al. Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents
US7067488B2 (en) Modified GLP-1 peptides with increased biological potency
CN115947821A (zh) 一种glp-1类似物
CN115463208B (zh) 一种口服降糖组合物
Sethi et al. INSIGHTS INTO INCRETINS IN DIABETES MANAGEMENT
EP4090351B1 (en) Dosing regimen of glp-1
CN101766811A (zh) 艾塞那肽或其类似物在制备治疗或预防糖尿病合并脑梗塞药物中的用途
Potenza et al. Targeting the incretin system in type 2 diabetes mellitus
Meier et al. GLP-1, incretin mimetics and DPP 4 inhibitors: new ways in the treatment of type 2 diabetes
US20090233851A1 (en) Insulin Resistance Improver
Vardhan et al. THE POTENTIAL OF LIXISENATIDE IN TREATING PATIENTS WITH TYPE 2 DIABETES MELLITUS

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20081127